This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Effects of Bupropion Augmentation in Escitalopram-Resistant Patients With Major Depressive Disorder: An Open-Label, Naturalistic Study

Article Abstract

Letter to the Editor

Sir: There is a pressing need for improvement of treatment response
to antidepressants in depression. Increasing evidence shows
that bupropion, a norepinephrine and dopamine reuptake inhibitor,
is one of the most widely chosen and effective augmenting
agents for depressive patients with insufficient response to serotonin
reuptake inhibitors. In this study, we evaluated the efficacy
and tolerability of bupropion augmentation in nonresponders to
escitalopram monotherapy in order to better understand this potential
approach to improving treatment outcome in depression.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 70

Quick Links: Depression (MDD)